Toth Financial Advisory Corp lowered its position in Stryker Corp. (NYSE:SYK) by 1.3% during the third quarter, Holdings Channel reports. The firm owned 77,752 shares of the medical technology company’s stock after selling 1,013 shares during the period. Stryker Corp. makes up approximately 2.7% of Toth Financial Advisory Corp’s holdings, making the stock its 2nd largest position. Toth Financial Advisory Corp’s holdings in Stryker Corp. were worth $9,051,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of SYK. LSV Asset Management acquired a new stake in Stryker Corp. during the second quarter worth about $107,000. Global X Management Co. LLC increased its stake in Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock worth $119,000 after buying an additional 698 shares during the period. Carroll Financial Associates Inc. increased its stake in Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock worth $130,000 after buying an additional 476 shares during the period. CWM LLC acquired a new stake in Stryker Corp. during the second quarter worth about $150,000. Finally, Daiwa SB Investments Ltd. acquired a new stake in Stryker Corp. during the third quarter worth about $163,000. 74.90% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Stryker Corp. (NYSE:SYK)

Shares of Stryker Corp. (NYSE:SYK) traded up 2.53% on Tuesday, hitting $115.81. The stock had a trading volume of 1,123,016 shares. Stryker Corp. has a 52 week low of $86.68 and a 52 week high of $123.55. The company has a market cap of $43.37 billion, a price-to-earnings ratio of 26.36 and a beta of 0.86. The firm has a 50 day moving average price of $113.51 and a 200-day moving average price of $115.06.

Stryker Corp. (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter last year, the firm earned $1.25 EPS. Stryker Corp.’s revenue for the quarter was up 17.1% compared to the same quarter last year. Analysts anticipate that Stryker Corp. will post $5.78 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be viewed at http://www.financial-market-news.com/stryker-corp-syk-shares-sold-by-toth-financial-advisory-corp/1208738/.

A number of research firms recently issued reports on SYK. Zacks Investment Research downgraded shares of Stryker Corp. from a “buy” rating to a “hold” rating in a research report on Monday, November 14th. SunTrust Banks Inc. initiated coverage on Stryker Corp. in a report on Thursday, October 13th. They issued a “buy” rating and a $140.00 price target for the company. BMO Capital Markets upgraded Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 price target for the company in a report on Tuesday, November 1st. They noted that the move was a valuation call. Oppenheimer Holdings Inc. set a $122.00 price target on Stryker Corp. and gave the stock a “hold” rating in a report on Sunday, October 30th. Finally, Canaccord Genuity set a $127.00 price target on Stryker Corp. and gave the stock a “buy” rating in a report on Sunday, October 30th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $122.38.

In related news, Director Ronda E. Stryker sold 6,000 shares of the business’s stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $115.67, for a total value of $694,020.00. Following the sale, the director now owns 193,142 shares of the company’s stock, valued at approximately $22,340,735.14. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Yin C. Becker sold 1,111 shares of the business’s stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $117.00, for a total value of $129,987.00. Following the completion of the sale, the vice president now directly owns 16,939 shares in the company, valued at approximately $1,981,863. The disclosure for this sale can be found here. Insiders own 7.80% of the company’s stock.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corp. (NYSE:SYK).

Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.